Haleon plc (LSE/NYSE: LON:HLN), a global leader in consumer health products, today published a supplement to its Euro Medium Term Note (EMTN) Programme. The supplement updates the base listing particulars dated May 3, 2024, for Haleon UK Capital plc's and Haleon Netherlands Capital B.V.'s £10 billion EMTN Programme, which is guaranteed by Haleon plc.
The EMTN Programme supplement, now available for stakeholders, provides updated information relevant to investors and is accessible through Haleon's website under the debt investors section.
This announcement follows the company's commitment to transparency in its financial activities. Haleon, known for its portfolio of health products including Advil, Sensodyne, and Centrum, emphasizes that the Base Listing Particulars are targeted at residents of specific countries and should not be relied upon by individuals outside of those jurisdictions or to whom the offer is not addressed.
The company's purpose is to deliver better everyday health with humanity, and its range of products covers Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, as well as Vitamins, Minerals, and Supplements.
Investors and media can direct their inquiries to Haleon's investor relations and corporate media contacts provided in the press release statement. The company has taken care to ensure that the information is presented in accordance with the rules and regulations of the Securities Exchange Act of 1934, with the report being duly signed by Amanda Mellor, Company Secretary, today.
The information contained in this article is based on a press release statement.
In other recent news, Haleon, a global consumer health company, has launched Eroxon®, the first FDA-cleared over-the-counter gel for the treatment of erectile dysfunction in the United States. The product, which is currently available for pre-order, is expected to be available at major retailers in October 2024. Eroxon® is a significant development in the sexual health market, as it can help men achieve an erection within 10 minutes, faster than other prescription treatments.
In relation to its corporate structure, Haleon recently announced the appointment of two new board members, Alan Stewart and Nancy Avila, who bring a wealth of experience in corporate finance, business transformation, and digital strategy. The company also disclosed its total number of shares with voting rights, which stands at 9,123,638,944, each with a nominal value of £0.01.
Regarding financial analysis, Haleon has been subject to various analyst ratings. Goldman Sachs (NYSE:GS) downgraded the company's stock from "Buy" to "Neutral," citing overvaluation. On the other hand, Berenberg initiated coverage with a "Buy" rating, anticipating organic sales growth and the successful launch of Eroxon in the U.S. market. These are recent developments and reflect a dynamic period for Haleon.
InvestingPro Insights
In light of Haleon plc's recent update to its EMTN Programme, investors may find additional context from real-time data and InvestingPro Tips useful for making informed decisions. With a market capitalization of $46.69 billion and an impressive gross profit margin of 62.54% over the last twelve months as of Q2 2024, Haleon demonstrates strong financial health. The company's stock has also been performing robustly, with a 21.88% return over the last three months and trading near its 52-week high, reflecting investor confidence.
According to InvestingPro Tips, Haleon operates with a moderate level of debt, which suggests a balanced approach to leverage and growth. Moreover, analysts predict the company will be profitable this year, aligning with Haleon's positive gross profit and recent performance. For those interested in a deeper dive, there are over 8 additional InvestingPro Tips available, offering more nuanced insights into Haleon's financial standing and market potential.
The P/E ratio of 31.5 indicates that investors are willing to pay a higher price for earnings, possibly due to expected growth or a strong track record. Despite a slight revenue decline of 1.31% over the last twelve months as of Q2 2024, the company's solid fundamentals and the strategic importance of its health products portfolio may continue to attract investor interest. For further details and a comprehensive analysis, investors can refer to the full suite of InvestingPro metrics and tips at https://www.investing.com/pro/HLN.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.